Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 200

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 200
---
 shared expenses primarily relate to our general and administrative functions, our non-laboratory facility space in our corporate headquarters and our production laboratory. We use the relative direct headcount assigned to each of the respective segments and our production laboratory sample volume to allocate these expenses. We do not allocate certain expenses, such as our corporate insurance costs, external legal and audit costs and expenses related to our investor relations, chief executive officer and other related support functions. Additionally, we do not allocate costs related to our idle facility in Seattle, Washington, interest expense related to our Purchase Agreement nor interest and other income, net. Given these unallocated costs and income are not included in the measurements reviewed by the CODM to assess each segment's performance, they are included in an "Unallocated Corporate" category. Our allocation methodology will be periodically evaluated and may change. Our CODM is not regularly provided and does not review assets to assess each segment's performance, make strategic decisions or allocate resources. As such, assets for reportable segments are not disclosed. Segment information for the years ended December 31, 2023 and 2022 are presented on a comparable basis to that of the current period and is based on judgments and allocation methods from our organizational changes implemented during the three months ended March 31, 2024.

118

Adaptive Biotechnologies CorporationNotes to Consolidated Financial Statements (Continued) 

The following tables set forth our segment information, including significant segment expenses that are (or are easily computable from) information regularly provided to our CODM, for the years ended December 31, 2024, 2023 and 2022 (in thousands): 

        Year Ended December 31,

        2024

        2023

        2022

        MRD:

        Revenue
         
        $
        145,529

        $
        102,739

        $
        87,144

        Less:

        Cost of revenue

        64,177

        63,273

        42,606

        Research and development

        40,743

        42,153

        31,768

        Sales and marketing

        77,579

        76,742

        65,558

        General and administrative

        40,446

        46,961

        32,349

        Other segment items(1)

        2,819

        —

        —

        Add back:

        Items to reconcile